Skip to content
10-K

Annual Report

Spero Therapeutics, Inc. SPRO

0000950170-25-046125

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 21, 2025 55.9M sh
Shares Diluted FY 2024 · Dec 31, 2023 52.99M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$33M
Cash And Equivalents FY 2024 · Dec 31, 2023 $76.33M
Current Liabilities FY 2024 · Dec 31, 2023 $37.15M
Total Liabilities FY 2024 · Dec 31, 2023 $75.5M
Current Assets FY 2024 · Dec 31, 2023 $131.21M
Total Assets FY 2024 · Dec 31, 2023 $182.39M
Eps Diluted FY 2024 · Dec 31, 2023 $0.43
Eps Basic FY 2024 · Dec 31, 2023 $0.43
Sga Expense FY 2024 · Dec 31, 2023 $25.55M
Rd Expense FY 2024 · Dec 31, 2023 $51.44M
Net Income FY 2024 · Dec 31, 2023 $22.81M
Operating Income FY 2024 · Dec 31, 2023 $21.48M
Revenue FY 2024 · Dec 31, 2023 $933K
Stockholders Equity FY 2024 · Dec 31, 2022 $75.93M